Last reviewed · How we verify
NCT06926075: ADVICE
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
Phase 1, PHASE2 trial testing A novel hGIIA-Vimentin Inhibitor in Prostate Cancers in 80 participants. Currently enrolling.
26 October 2027
Quick facts
| Lead sponsor | Filamon LTD |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 80 |
| Start date | 7 November 2025 |
| Primary completion | 26 October 2027 |
| Estimated completion | 26 October 2027 |
| Sites | 3 locations across Australia |
Drugs / interventions tested
- A novel hGIIA-Vimentin Inhibitor — full drug profile →
- Dose expansion — full drug profile →
Conditions studied
- Prostate Cancers — all drugs for Prostate Cancers →
- Breast Cancer — all drugs for Breast Cancer →
- Lung Cancers — all drugs for Lung Cancers →
- Ovarian Cancer — all drugs for Ovarian Cancer →
Sponsor
Filamon LTD — full company profile →
Who can join
18 and older, any sex, with Prostate Cancers or Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical trial is an adaptive study of a novel vimentin inhibitor in cancers. It is an open label, multicentre, single ascending dose level in phase I and cohort exploration in phase II. Primary objective is to evaluate safety and tolerability of KESONOTIDE™ as a monotherapy in participants with advanced/metastatic solid cancers. Secondary objective is to characterise the pharmacokinetics of KESONOTIDE™. Phase I study will enrol 20-32 participants and Phase II approximately 80 participants.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06926075
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostate Cancers
Currently open trials in the same condition.
- NCT06717295 — The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cel · recruiting
- NCT06970275 — To Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopatho · recruiting
- NCT07038369 — A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations · Phase 1 · active not recruiting
- NCT06960291 — Sustainable Implementation of the EXCEL Exercise Oncology Program Across Canada · NA · recruiting
- NCT06683846 — Ivonescimab in the Treatment of Multiple Advanced Tumors · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06926075 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Filamon LTD
- Last refreshed: 17 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06926075.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing